- IBDEI10L ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,16499,1,4,0)
- ;;=4^D56.2
- ;;^UTILITY(U,$J,358.3,16499,2)
- ;;=^340496
- ;;^UTILITY(U,$J,358.3,16500,0)
- ;;=D75.9^^61^775^60
- ;;^UTILITY(U,$J,358.3,16500,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16500,1,3,0)
- ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
- ;;^UTILITY(U,$J,358.3,16500,1,4,0)
- ;;=4^D75.9
- ;;^UTILITY(U,$J,358.3,16500,2)
- ;;=^5002393
- ;;^UTILITY(U,$J,358.3,16501,0)
- ;;=D59.0^^61^775^63
- ;;^UTILITY(U,$J,358.3,16501,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16501,1,3,0)
- ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
- ;;^UTILITY(U,$J,358.3,16501,1,4,0)
- ;;=4^D59.0
- ;;^UTILITY(U,$J,358.3,16501,2)
- ;;=^5002323
- ;;^UTILITY(U,$J,358.3,16502,0)
- ;;=D59.2^^61^775^64
- ;;^UTILITY(U,$J,358.3,16502,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16502,1,3,0)
- ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
- ;;^UTILITY(U,$J,358.3,16502,1,4,0)
- ;;=4^D59.2
- ;;^UTILITY(U,$J,358.3,16502,2)
- ;;=^5002325
- ;;^UTILITY(U,$J,358.3,16503,0)
- ;;=R59.9^^61^775^67
- ;;^UTILITY(U,$J,358.3,16503,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16503,1,3,0)
- ;;=3^Enlarged Lymph Nodes,Unspec
- ;;^UTILITY(U,$J,358.3,16503,1,4,0)
- ;;=4^R59.9
- ;;^UTILITY(U,$J,358.3,16503,2)
- ;;=^5019531
- ;;^UTILITY(U,$J,358.3,16504,0)
- ;;=D47.3^^61^775^68
- ;;^UTILITY(U,$J,358.3,16504,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16504,1,3,0)
- ;;=3^Essential Thrombocythemia
- ;;^UTILITY(U,$J,358.3,16504,1,4,0)
- ;;=4^D47.3
- ;;^UTILITY(U,$J,358.3,16504,2)
- ;;=^5002258
- ;;^UTILITY(U,$J,358.3,16505,0)
- ;;=C82.09^^61^775^69
- ;;^UTILITY(U,$J,358.3,16505,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16505,1,3,0)
- ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,16505,1,4,0)
- ;;=4^C82.09
- ;;^UTILITY(U,$J,358.3,16505,2)
- ;;=^5001470
- ;;^UTILITY(U,$J,358.3,16506,0)
- ;;=C82.00^^61^775^70
- ;;^UTILITY(U,$J,358.3,16506,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16506,1,3,0)
- ;;=3^Follicular Lymphoma Grade I,Unspec Site
- ;;^UTILITY(U,$J,358.3,16506,1,4,0)
- ;;=4^C82.00
- ;;^UTILITY(U,$J,358.3,16506,2)
- ;;=^5001461
- ;;^UTILITY(U,$J,358.3,16507,0)
- ;;=C82.19^^61^775^71
- ;;^UTILITY(U,$J,358.3,16507,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16507,1,3,0)
- ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,16507,1,4,0)
- ;;=4^C82.19
- ;;^UTILITY(U,$J,358.3,16507,2)
- ;;=^5001480
- ;;^UTILITY(U,$J,358.3,16508,0)
- ;;=C82.10^^61^775^72
- ;;^UTILITY(U,$J,358.3,16508,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16508,1,3,0)
- ;;=3^Follicular Lymphoma Grade II,Unspec Site
- ;;^UTILITY(U,$J,358.3,16508,1,4,0)
- ;;=4^C82.10
- ;;^UTILITY(U,$J,358.3,16508,2)
- ;;=^5001471
- ;;^UTILITY(U,$J,358.3,16509,0)
- ;;=C82.29^^61^775^73
- ;;^UTILITY(U,$J,358.3,16509,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16509,1,3,0)
- ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,16509,1,4,0)
- ;;=4^C82.29
- ;;^UTILITY(U,$J,358.3,16509,2)
- ;;=^5001490
- ;;^UTILITY(U,$J,358.3,16510,0)
- ;;=C82.20^^61^775^74
- ;;^UTILITY(U,$J,358.3,16510,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16510,1,3,0)
- ;;=3^Follicular Lymphoma Grade III,Unspec Site
- ;;^UTILITY(U,$J,358.3,16510,1,4,0)
- ;;=4^C82.20
- ;;^UTILITY(U,$J,358.3,16510,2)
- ;;=^5001481
- ;;^UTILITY(U,$J,358.3,16511,0)
- ;;=C82.39^^61^775^75
- ;;^UTILITY(U,$J,358.3,16511,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,16511,1,3,0)
- ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10L 3809 printed Jan 18, 2025@03:00:37 Page 2
- IBDEI10L ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,16499,1,4,0)
- +2 ;;=4^D56.2
- +3 ;;^UTILITY(U,$J,358.3,16499,2)
- +4 ;;=^340496
- +5 ;;^UTILITY(U,$J,358.3,16500,0)
- +6 ;;=D75.9^^61^775^60
- +7 ;;^UTILITY(U,$J,358.3,16500,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,16500,1,3,0)
- +10 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
- +11 ;;^UTILITY(U,$J,358.3,16500,1,4,0)
- +12 ;;=4^D75.9
- +13 ;;^UTILITY(U,$J,358.3,16500,2)
- +14 ;;=^5002393
- +15 ;;^UTILITY(U,$J,358.3,16501,0)
- +16 ;;=D59.0^^61^775^63
- +17 ;;^UTILITY(U,$J,358.3,16501,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,16501,1,3,0)
- +20 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
- +21 ;;^UTILITY(U,$J,358.3,16501,1,4,0)
- +22 ;;=4^D59.0
- +23 ;;^UTILITY(U,$J,358.3,16501,2)
- +24 ;;=^5002323
- +25 ;;^UTILITY(U,$J,358.3,16502,0)
- +26 ;;=D59.2^^61^775^64
- +27 ;;^UTILITY(U,$J,358.3,16502,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,16502,1,3,0)
- +30 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
- +31 ;;^UTILITY(U,$J,358.3,16502,1,4,0)
- +32 ;;=4^D59.2
- +33 ;;^UTILITY(U,$J,358.3,16502,2)
- +34 ;;=^5002325
- +35 ;;^UTILITY(U,$J,358.3,16503,0)
- +36 ;;=R59.9^^61^775^67
- +37 ;;^UTILITY(U,$J,358.3,16503,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,16503,1,3,0)
- +40 ;;=3^Enlarged Lymph Nodes,Unspec
- +41 ;;^UTILITY(U,$J,358.3,16503,1,4,0)
- +42 ;;=4^R59.9
- +43 ;;^UTILITY(U,$J,358.3,16503,2)
- +44 ;;=^5019531
- +45 ;;^UTILITY(U,$J,358.3,16504,0)
- +46 ;;=D47.3^^61^775^68
- +47 ;;^UTILITY(U,$J,358.3,16504,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,16504,1,3,0)
- +50 ;;=3^Essential Thrombocythemia
- +51 ;;^UTILITY(U,$J,358.3,16504,1,4,0)
- +52 ;;=4^D47.3
- +53 ;;^UTILITY(U,$J,358.3,16504,2)
- +54 ;;=^5002258
- +55 ;;^UTILITY(U,$J,358.3,16505,0)
- +56 ;;=C82.09^^61^775^69
- +57 ;;^UTILITY(U,$J,358.3,16505,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,16505,1,3,0)
- +60 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
- +61 ;;^UTILITY(U,$J,358.3,16505,1,4,0)
- +62 ;;=4^C82.09
- +63 ;;^UTILITY(U,$J,358.3,16505,2)
- +64 ;;=^5001470
- +65 ;;^UTILITY(U,$J,358.3,16506,0)
- +66 ;;=C82.00^^61^775^70
- +67 ;;^UTILITY(U,$J,358.3,16506,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,16506,1,3,0)
- +70 ;;=3^Follicular Lymphoma Grade I,Unspec Site
- +71 ;;^UTILITY(U,$J,358.3,16506,1,4,0)
- +72 ;;=4^C82.00
- +73 ;;^UTILITY(U,$J,358.3,16506,2)
- +74 ;;=^5001461
- +75 ;;^UTILITY(U,$J,358.3,16507,0)
- +76 ;;=C82.19^^61^775^71
- +77 ;;^UTILITY(U,$J,358.3,16507,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,16507,1,3,0)
- +80 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
- +81 ;;^UTILITY(U,$J,358.3,16507,1,4,0)
- +82 ;;=4^C82.19
- +83 ;;^UTILITY(U,$J,358.3,16507,2)
- +84 ;;=^5001480
- +85 ;;^UTILITY(U,$J,358.3,16508,0)
- +86 ;;=C82.10^^61^775^72
- +87 ;;^UTILITY(U,$J,358.3,16508,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,16508,1,3,0)
- +90 ;;=3^Follicular Lymphoma Grade II,Unspec Site
- +91 ;;^UTILITY(U,$J,358.3,16508,1,4,0)
- +92 ;;=4^C82.10
- +93 ;;^UTILITY(U,$J,358.3,16508,2)
- +94 ;;=^5001471
- +95 ;;^UTILITY(U,$J,358.3,16509,0)
- +96 ;;=C82.29^^61^775^73
- +97 ;;^UTILITY(U,$J,358.3,16509,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,16509,1,3,0)
- +100 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
- +101 ;;^UTILITY(U,$J,358.3,16509,1,4,0)
- +102 ;;=4^C82.29
- +103 ;;^UTILITY(U,$J,358.3,16509,2)
- +104 ;;=^5001490
- +105 ;;^UTILITY(U,$J,358.3,16510,0)
- +106 ;;=C82.20^^61^775^74
- +107 ;;^UTILITY(U,$J,358.3,16510,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,16510,1,3,0)
- +110 ;;=3^Follicular Lymphoma Grade III,Unspec Site
- +111 ;;^UTILITY(U,$J,358.3,16510,1,4,0)
- +112 ;;=4^C82.20
- +113 ;;^UTILITY(U,$J,358.3,16510,2)
- +114 ;;=^5001481
- +115 ;;^UTILITY(U,$J,358.3,16511,0)
- +116 ;;=C82.39^^61^775^75
- +117 ;;^UTILITY(U,$J,358.3,16511,1,0)
- +118 ;;=^358.31IA^4^2
- +119 ;;^UTILITY(U,$J,358.3,16511,1,3,0)
- +120 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites